Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 51 to 100 of 159 results for urinary tract infections

  1. Transvaginal laser therapy for urogenital atrophy (HTG582)

    Evidence-based recommendations on transvaginal laser therapy for urogenital atrophy. This involves using a laser in the vagina to increase its strength and elasticity, to improve symptoms of urogenital atrophy.

  2. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  3. Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids (HTG12)

    Evidence-based recommendations on magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids. This involves passing laser heat through needles inserted into the fibroid to destroy it.

  4. Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention (HTG685)

    Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.

  5. Surgical site infections: prevention and treatment (NG125)

    This guideline covers preventing and treating surgical site infections in adults, young people and children who are having a surgical procedure involving a cut through the skin. It focuses on methods used before, during and after surgery to minimise the risk of infection.

  6. Physical health of people in prison (NG57)

    This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

  7. Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)

    NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .

  8. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for stress urinary incontinence

    Surgery for stress urinary incontinence Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last...

  9. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for vaginal vault prolapse

    fixation with sutures than after sacrocolpopexy with mesh. These are: stress urinary incontinence (leaking urine, especially during...

  10. Pyelonephritis (acute): antimicrobial prescribing (NG111)

    This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

  11. Electrocautery cutting balloon treatment for pelviureteric junction obstruction (HTG205)

    Evidence-based recommendations on electrocautery cutting balloon treatment for pelviureteric junction obstruction. This involves widening the renal pelvis by inserting a catheter with a balloon and wire into the urinary tract.

  12. Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1)

    This guideline covers diagnosing and managing gastro-oesophageal reflux disease in children and young people (under 18s). It aims to raise awareness of symptoms that need investigating and treating, and to reassure parents and carers that regurgitation is common in infants under 1 year.

  13. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

  14. Renal and ureteric stones (QS195)

    This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.

  15. QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

    NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .

  16. Intrapartum care (NG235)

    This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.

  17. MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)

    NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .

  18. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    They include: : Infections, including vaginal infections and urinary tract infections. : Wound complications,...

  19. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

  20. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

    Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

  21. Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)

    Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.

  22. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)

    Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.

  23. Gastro-oesophageal reflux in children and young people (QS112)

    This quality standard covers managing symptoms of reflux (regurgitation or bringing up feeds) in babies, children and young people (under 18). It also covers diagnosing and managing gastro-oesophageal reflux disease (also called GORD), which is more severe reflux and heartburn. It describes high-quality care in priority areas for improvement.

  24. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG639)

    Evidence-based recommendations on prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves positioning a temporary implant in the urethra to increase the flow of urine.

  25. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for stress urinary incontinence – Options for women referred to specialist centres

    stress urinary incontinence 1 This decision aid is for women who have complications caused by pelvic mesh that was used to treat their...

  26. Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG691)

    Evidence-based recommendations on transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves injecting a high-speed jet of water into the prostate to destroy some of the prostate tissue and widen the urethra.

  27. Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)

    Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam

  28. Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction (HTG129)

    Evidence-based recommendations on fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. This involves inserting a cannula through the mother's abdominal and uterine walls into the amniotic cavity and subsequently into the bladder of the fetus.

  29. Intramural urethral bulking procedures for stress urinary incontinence in women (HTG86)

    Evidence-based recommendations on intramural urethral bulking procedures for stress urinary incontinence in women. Intramural urethral bulking aims to augment the urethral wall and increase the urethral closure force.

  30. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG469)

    Evidence-based recommendations on prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves blocking the blood vessels supplying the prostate with tiny plastic particles.

  31. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (AMR1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

  32. Neonatal infection: antibiotics for prevention and treatment (NG195)

    This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.

  33. Antimicrobial prescribing: meropenem with vaborbactam (ES21)

    Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making

  34. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (HTG578)

    Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.

  35. Retrograde urethral sphincterometry (HTG109)

    Evidence-based recommendations on retrograde uretral sphincterometry. This involves passing fluid through a small, cone-shaped device placed into the urethra to display the pressure needed to open the urethra sphincter.

  36. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

  37. Clostridioides difficile infection: antimicrobial prescribing (NG199)

    This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.

  38. Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment (HTG753)

    Late-stage assessment (LSA) guidance on intermittent urethral catheters for chronic incomplete bladder emptying in adults.

  39. Sacral nerve stimulation for urge incontinence and urgency-frequency (HTG37)

    Evidence-based recommendations on sacral nerve stimulation for urge incontinence and urgency-frequency. This involves placing electrodes and connecting them to an implantable pulse generator.

  40. Faltering growth: recognition and management of faltering growth in children (NG75)

    This guideline covers recognition, assessment and monitoring of faltering growth in infants and children. It includes a definition of growth thresholds for concern and identifying the risk factors for, and possible causes of, faltering growth. It also covers interventions, when to refer, service design, and information and support.

  41. Bone-anchored cystourethropexy (HTG6)

    Evidence-based recommendations on bone-anchored cystourethropexy for treating stress urinary incontinence in women. Bone-anchored cystourethropexy is a minimally invasive bladder neck needle suspension procedure.

  42. Peristeen Plus transanal irrigation system for managing bowel dysfunction (HTG462)

    Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction.

  43. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

  44. Child maltreatment: when to suspect maltreatment in under 18s (CG89)

    This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.

  45. Routine preoperative tests for elective surgery (NG45)

    This guideline covers routine preoperative tests for people aged over 16 who are having elective surgery. It aims to reduce unnecessary testing by advising which tests to offer people before minor, intermediate and major or complex surgery, taking into account specific comorbidities (cardiovascular, renal and respiratory conditions and diabetes and obesity). It does not cover pregnant women or people having cardiothoracic procedures or neurosurgery.

  46. Endopyelotomy for pelviureteric junction obstruction (HTG206)

    Evidence-based recommendations on endopyelotomy for pelviureteric junction obstruction. This involves widening the renal pelvis by inserting small instruments either up through the urinary tract or down through the skin and into the kidney.